Table 1.
Baseline characteristics of the control and treatment groups
| Treatment group (Quadra) (77) | Control group (Bipolar) (77) | P value | |
|---|---|---|---|
| Demographics | |||
| Age (years) | 69.4 ± 9.8 | 69.6 ± 9.4 | 0.86 |
| Gender (male) | 61 (79.2%) | 60 (77.9%) | 0.95 |
| LVEF (%) | 25.6 ± 6.1 | 25.6 ± 6.9 | 0.93 |
| NYHA (class) | 2.7 ± 0.6 | 2.7 ± 0.6 | 0.69 |
| Follow-up (years) | 1.65 ± 0.8 | 1.84 ± 1.2 | 0.005 |
| Comorbidities | |||
| CAD | 40 (51.9%) | 43 (55.8%) | 0.79 |
| Hypertension | 68 (88.3%) | 68 (88.3%) | 1.00 |
| History of AF | 15 (19.5%) | 16 (20.8%) | 0.87 |
| Diabetes | 24 (31.2%) | 29 (37.7%) | 0.55 |
| Primary prevention | 72 (93.5%) | 68 (88.3%) | 0.80 |
| Previous cardiac surgery | 13 (16.9%) | 14 (18.2%) | 0.85 |
| Valvular disease | 40 (51.9%) | 36 (46.8%) | 0.71 |
| Medications | |||
| Nitrates | 11 (14.3%) | 11 (14.3%) | 1.00 |
| Diuretics | 72 (93.5%) | 72 (93.5%) | 1.00 |
| β-Blockers | 62 (80.5%) | 63 (81.8%) | 0.94 |
| ARBs/ACE | 65 (84.4%) | 67 (87.0%) | 0.89 |
| Aldosterone antagonists | 47 (61.0%) | 38 (49.4%) | 0.43 |
ACE, angiotensin-converting enzyme; AF, atrial fibrillation; ARBs, angiotensin II receptors blockers; CAD, coronary artery disease; EF, ejection fraction; LV, left ventricular.